| ［1］ |
Burki T.European Commission classifies obesity as a chronic disease［J］.Lancet Diabetes Endocrinol，2021，9（7）：418.
|
| ［2］ |
Jin X，Qiu T，Li L，et al.Pathophysiology of obesity and its associated diseases ［J］.Acta Pharm Sin B，2023，13（6）：2403-2424.
|
| ［3］ |
World Obesity Federation.World Obesity Atlas 2024 ［EB/OL］.（2024-03-04）［2024-03-28］.https：//data.worldo-besity.org/publications/？cat=22.
|
| ［4］ |
Noria SF，Shelby RD，Atkins KD，et al.Weight Regain After Bariatric Surgery：Scope of the Problem，Causes，Prevention，and Treatment ［J］.Curr Diab Rep，2023，23（3）：31-42.
|
| ［5］ |
Ahmad NN，Robinson S，Kennedy-Martin T，et al.Clinical outcomes associated with anti-obesity medications in real-world practice：A systematic literature review ［J］.Obes Rev，2021，22（11）：e13326.
|
| ［6］ |
Yao H，Zhang A，Li D，et al.Comparative effectiveness of GLP-1 receptor agonists on glycaemic control，body weight，and lipid profile for type 2 diabetes：systematic review and network meta-analysis ［J］.BMJ，2024，384：e076410.
|
| ［7］ |
Liu Y，Ruan B，Jiang H，et al.The weight-loss effect of GLP-1RAs glucagon-Like peptide-1 receptor agonists in non-diabetic individuals with overweight or obesity：A systematic review with Meta-Analysis and trial sequential analysis of randomized controlled trials ［J］.Am J Clin Nutr，2023，118（3）：614-626.
|
| ［8］ |
Blundell J，Finlayson G，Axelsen M，et al.Effects of once-weekly semaglutide on appetite，energy intake，control of eating，food preference and body weight in subjects with obesity ［J］.Diabetes Obes Metab，2017，19（9）：1242-1251.
|
| ［9］ |
Amaro A，Sugimoto D，Wharton S.Efficacy and safety of semaglutide for weight management：evidence from the STEP program ［J］.Postgrad Med，2022，134（sup1）：5-17.
|
| ［10］ |
Weghuber D，Barrett T，Barrientos-Pérez M，et al.once-weekly semaglutide in adolescents with obesity ［J］.N Engl J Med，2022，387（24）：2245-2257.
|
| ［11］ |
Kosiborod MN，Abildstrøm SZ，Borlaug BA，et al.Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity ［J］.N Engl J Med，2023，389（12）：1069-1084.
|
| ［12］ |
Kosiborod MN，Petrie MC，Borlaug BA，et al.semaglutide in patients with obesity-related heart failure and type 2 diabetes ［J］.N Engl J Med，2024，390（15）：1394-1407.
|
| ［13］ |
Yao H，Zhang A，Li D，et al.Comparative effectiveness of GLP-1 receptor agonists on glycaemic control，body weight，and lipid profile for type 2 diabetes：systematic review and network meta-analysis ［J］.BMJ，2024，384：e076410.
|
| ［14］ |
Smits MM，Van Raalte DH.Safety of Semaglutide ［J］.Front Endocrinol （Lausanne），2021，12：645563.
|
| ［15］ |
Nagendra L，Bg H，Sharma M，et al.Semaglutide and cancer：A systematic review and meta-analysis ［J］.Diabetes Metab Syndr，2023，17（9）：102834.
|
| ［16］ |
Baldini G，Phelan KD.The melanocortin pathway and control of appetite-progress and therapeutic implications ［J］.J Endocrinol，2019，241（1）：R1-R33.
|
| ［17］ |
Sharma S，Garfield AS，Shah B，et al.Current mechanistic and pharmacodynamic understanding of melanocortin-4 receptor activation ［J］.Molecules，2019，24（10）：1892.
|
| ［18］ |
Clément K，van den Akker E，Argente J，et al.Efficacy and safety of setmelanotide，an MC4R agonist，in individuals with severe obesity due to LEPR or POMC deficiency：single-arm，open-label，multicentre，phase 3 trials ［J］.Lancet Diabetes Endocrinol，2020，8（12）：960-970.
|
| ［19］ |
Haqq AM，Chung WK，Dollfus H，et al.Efficacy and safety of setmelanotide，a melanocortin-4 receptor agonist，in patients with Bardet-Biedl syndrome and Alström syndrome：a multicentre，randomised，double-blind，placebo-controlled，phase 3 trial with an open-label period ［J］.Lancet Diabetes Endocrinol，2022，10（12）：859-868.
|
| ［20］ |
Trapp CM，Censani M.Setmelanotide：a promising advancement for pediatric patients with rare forms of genetic obesity ［J］.Curr Opin Endocrinol Diabetes Obes，2023，30（2）：136-140.
|
| ［21］ |
Roth CL，Scimia C，Shoemaker AH，et al.Setmelanotide for the treatment of acquired hypothalamic obesity：a phase 2，open-label，multicentre trial ［J］.Lancet Diabetes Endocrinol，2024，12（6）：380-389.
|
| ［22］ |
Pressley H，Cornelio CK，Adams EN.Setmelanotide：A novel targeted treatment for monogenic obesity ［J］.J Pharm Technol，2022，38（6）：368-373.
|
| ［23］ |
Ferraz Barbosa B，Aquino de Moraes FC，Bordignon Barbosa C，et al.Efficacy and safety of setmelanotide，a melanocortin-4 receptor agonist，for obese patients：A systematic review and Meta-analysis ［J］.J Pers Med，2023，13（10）：1460.
|
| ［24］ |
Fisman EZ，Tenenbaum A.The dual glucose-dependent insulinotropic polypeptide （GIP） and glucagon-like peptide-1 （GLP-1） receptor agonist tirzepatide：a novel cardiometabolic therapeutic prospect ［J］.Cardiovasc Diabetol，2021，20（1）：225.
|
| ［25］ |
Jastreboff AM，Aronne LJ，Ahmad NN，et al.Tirzepatide once weekly for the treatment of obesity ［J］.N Engl J Med，2022，387（3）：205-216.
|
| ［26］ |
Zhao L，Cheng Z，Lu Y，et al.Tirzepatide for weight reduction in Chinese adults with obesity：The SURMOUNT-CN randomized clinical trial ［J］.JAMA，2024，332（7）：551-560.
|
| ［27］ |
Frías JP，Davies MJ，Rosenstock J，et al.Tirzepatide versus Semaglutide once weekly in patients with type 2 diabetes ［J］.N Engl J Med，2021，385（6）：503-515.
|
| ［28］ |
Sinha R，Papamargaritis D，Sargeant JA，et al.Efficacy and safety of Tirzepatide in Type 2 diabetes and obesity management ［J］.J Obes Metab Syndr，2023，32（1）：25-45.
|
| ［29］ |
Jastreboff AM，Kaplan LM，Frías JP，et al.triple-hormone-receptor agonist retatrutide for obesity — A phase 2 trial ［J］.N Engl J Med，2023，89（6）：514-526.
|
| ［30］ |
Rosenstock J，Frias J，Jastreboff AM，et al.Retatrutide，a GIP，GLP-1 and glucagon receptor agonist，for people with type 2 diabetes：a randomised，double-blind，placebo and active-controlled，parallelgroup，phase 2 trial conducted in the USA ［J］.Lancet，2023，402（10401）：529-544.
|
| ［31］ |
Kaur M，Misra S.A review of an investigational drug retatrutide，a novel triple agonist agent for the treatment of obesity ［J］.Eur J Clin Pharmacol，2024，80（5）：669-676.
|
| ［32］ |
Asiabar AS，Rezaei MA，Jafarzadeh D，et al.The cost-effectiveness analysis of semaglutide for the treatment of adult and adolescent patients with overweight and obesity：a systematic review ［J］.Eur J Clin Pharmaco，2024，80（12）：1857-1870.
|
| ［33］ |
Li Z，Zhang B，Wang N，et al.A novel peptide protects against dietinduced obesity by suppressing appetite and modulating the gut microbiota ［J］.Gut，2023，72（4）：686-698.
|
| ［34］ |
Chen W，Binbin G，Lidan S，et al.Evolution of peptide YY analogs for the management of type 2 diabetes and obesity ［J］.Bioorg Chem，2023，140：106808.
|
| ［35］ |
Mathiesen DS，Bagger JI，Knop FK.Long-acting amylin analogues for the management of obesity ［J］.Curr Opin Endocrinol Diabetes Obes，2022，29（2）：183-190.
|
| ［36］ |
Pena-Leon V，Perez-Lois R，Villalon M，et al.Novel mechanisms involved in leptin sensitization in obesity ［J］.Biochem Pharmacol，2024，223：116129.
|